Skip to main content

Advertisement

Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: Eukaryotic initiation factor 4A2 promotes experimental metastasis and oxaliplatin resistance in colorectal cancer

Fig. 6

Silvestrol (SIL) inhibits tumor growth and has synergistic effects with oxaliplatin (OXA) in CDX and PDX. a, b Mice planted with indicated cancer cells or PDX were treated as indicated. The group treated with SIL and OXA together showed the most significant decrease in tumor volume and weight in the CDX (a) and PDX (b) models. c The mice treated with SIL + OXA combination treatment showed the most significant decrease of Ki67-positive cells in IHC staining. d The mice treated with SIL + OXA combination treatment showed the most significant increase of apoptotic cells in TUNEL assays. *, P < 0.05; **, P < 0.01 versus the control

Back to article page